- Home
- TNGX vs CRUS Comparison
TNGX vs CRUS Comparison
Compare TNGX & CRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CRUS
- Stock Information
- Founded
- TNGX 2014
- CRUS 1984
- Country
- TNGX United States
- CRUS United States
- Employees
- TNGX N/A
- CRUS N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CRUS Semiconductors
- Sector
- TNGX Health Care
- CRUS Technology
- Exchange
- TNGX Nasdaq
- CRUS Nasdaq
- Market Cap
- TNGX 735.0M
- CRUS N/A
- IPO Year
- TNGX N/A
- CRUS 1989
- Fundamental
- Price
- TNGX $6.64
- CRUS $123.81
- Analyst Decision
- TNGX Strong Buy
- CRUS Buy
- Analyst Count
- TNGX 8
- CRUS 7
- Target Price
- TNGX $15.14
- CRUS $137.50
- AVG Volume (30 Days)
- TNGX 885.7K
- CRUS 551.9K
- Earning Date
- TNGX 11-06-2024
- CRUS 10-31-2024
- Dividend Yield
- TNGX N/A
- CRUS N/A
- EPS Growth
- TNGX N/A
- CRUS 101.03
- EPS
- TNGX N/A
- CRUS 5.40
- Revenue
- TNGX $42,509,000.00
- CRUS $1,845,900,000.00
- Revenue This Year
- TNGX $18.15
- CRUS $6.77
- Revenue Next Year
- TNGX N/A
- CRUS $6.34
- P/E Ratio
- TNGX N/A
- CRUS $22.95
- Revenue Growth
- TNGX 26.16
- CRUS 1.37
- 52 Week Low
- TNGX $6.33
- CRUS $65.02
- 52 Week High
- TNGX $13.01
- CRUS $147.46
- Technical
- Relative Strength Index (RSI)
- TNGX 37.15
- CRUS 52.43
- Support Level
- TNGX $6.83
- CRUS $122.37
- Resistance Level
- TNGX $7.47
- CRUS $126.04
- Average True Range (ATR)
- TNGX 0.37
- CRUS 3.17
- MACD
- TNGX 0.11
- CRUS 1.08
- Stochastic Oscillator
- TNGX 27.31
- CRUS 92.46
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.